Literature DB >> 18598320

Atorvastatin increases myocardial indices of oxidative stress in a porcine model of hypercholesterolemia and chronic ischemia.

Neel R Sodha1, Munir Boodhwani, Basel Ramlawi, Richard T Clements, Shigetoshi Mieno, Jun Feng, Shu-Hua Xu, Cesario Bianchi, Frank W Sellke.   

Abstract

BACKGROUND/AIM: Atorvastatin has previously been shown to reduce the endogenous angiogenic response to chronic ischemia in a porcine model. One possible mechanism for this effect is reduced bioavailability of nitric oxide, a key mediator of angiogenesis, secondary to increased oxygen free radicals. We sought to determine if atorvastatin modulates oxidative stress in myocardial tissue.
METHODS: Dietary induction of hypercholesterolemia was performed over 20 weeks in Yucatan swine with treated animals receiving atorvastatin 3 mg/kg/day. Chronic myocardial ischemia was induced via surgical placement of an ameroid constrictor ring around the proximal circumflex artery at age 20 weeks, followed by tissue harvest at age 27 weeks. Myocardial levels of protein, lipid, and DNA biomarkers of oxidative stress, serum levels of 8-isoprostane, nitric oxide (NO) dependent, and independent coronary microvascular reactivity, as well as isotope-labeled microsphere myocardial perfusion analysis and histologic analysis for endothelial cell density was performed.
RESULTS: Atorvastatin treatment was associated with elevated levels of myocardial protein oxidation and lipid peroxidation. Conversely, serum oxidant stress biomarkers were not elevated. Atorvastatin treatment improved nitric oxide dependent and independent microvascular reactivity, and was associated with decreased perfusion in the ischemic myocardial territory.
CONCLUSION: Treatment with atorvastatin was associated with increased levels of myocardial tissue protein and lipid oxidative stress biomarkers and a reduced functional endogenous angiogenic response, but improved coronary microvascular reactivity. Increased oxidative stress in tissues may play a role in the reduced angiogenic response seen with atorvastatin treatment in other studies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18598320      PMCID: PMC2629376          DOI: 10.1111/j.1540-8191.2008.00600.x

Source DB:  PubMed          Journal:  J Card Surg        ISSN: 0886-0440            Impact factor:   1.620


  40 in total

1.  Do the serum oxidative stress biomarkers provide a reasonable index of the general oxidative stress status?

Authors:  Sandro Argüelles; Sonia García; Mariam Maldonado; Alberto Machado; Antonio Ayala
Journal:  Biochim Biophys Acta       Date:  2004-11-01

Review 2.  The pro- and antiangiogenic effects of statins.

Authors:  Adriane Skaletz-Rorowski; Yasuko Kureishi; Ichiro Shiojima; Kenneth Walsh
Journal:  Semin Vasc Med       Date:  2004-11

3.  VEGF administration in chronic myocardial ischemia in pigs.

Authors:  J J Lopez; R J Laham; A Stamler; J D Pearlman; S Bunting; A Kaplan; J P Carrozza; F W Sellke; M Simons
Journal:  Cardiovasc Res       Date:  1998-11       Impact factor: 10.787

Review 4.  Molecular and cellular basis of myocardial angiogenesis.

Authors:  H J Granger; M Ziche; J R Hawker; C J Meininger; L E Czisny; D C Zawieja
Journal:  Cell Mol Biol Res       Date:  1994

5.  Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients.

Authors:  Stefan John; Markus P Schneider; Christian Delles; Johannes Jacobi; Roland E Schmieder
Journal:  Am Heart J       Date:  2005-03       Impact factor: 4.749

6.  Anti-oxidative effect of fluvastatin in hyperlipidemic type 2 diabetic patients.

Authors:  Shinnya Miwa; Hirotaka Watada; Chie Omura; Naoko Takayanagi; Kyoko Nishiyama; Yasushi Tanaka; Tomio Onuma; Ryuzo Kawamori
Journal:  Endocr J       Date:  2005-04       Impact factor: 2.349

7.  Rapid effect of pravastatin on endothelial function and lipid peroxidation in unstable angina.

Authors:  Emmanouil Karatzis; John Lekakis; Christos Papamichael; Ioanna Andreadou; Adriana Cimponeriu; Konstantinos Aznaouridis; Theodoros G Papaioannou; Athanassios Protogerou; Myron Mavrikakis
Journal:  Int J Cardiol       Date:  2005-05-11       Impact factor: 4.164

8.  Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: the Euroinject One trial.

Authors:  Jens Kastrup; Erik Jørgensen; Andreas Rück; Kristina Tägil; Dietmar Glogar; Witold Ruzyllo; Hans Erik Bøtker; Dariusz Dudek; Viktor Drvota; Birger Hesse; Leif Thuesen; Pontus Blomberg; Mariann Gyöngyösi; Christer Sylvén
Journal:  J Am Coll Cardiol       Date:  2005-04-05       Impact factor: 24.094

9.  Fluvastatin reduces oxidative stress, decreases serum monocyte chemotactic protein-1 level and improves endothelial function in patients with hypercholesterolemia.

Authors:  Hsin-Bang Leu; Chin-Cheng Wu; Tao-Cheng Wu; Shing-Jong Lin; Jaw-Wen Chen
Journal:  J Formos Med Assoc       Date:  2004-12       Impact factor: 3.282

10.  Myocardial VEGF expression after cardiopulmonary bypass and cardioplegia.

Authors:  M Tofukuji; C Metais; J Li; A Franklin; M Simons; F W Sellke
Journal:  Circulation       Date:  1998-11-10       Impact factor: 29.690

View more
  9 in total

1.  Ascorbic acid mitigates the myocardial injury after cardiac arrest and electrical shock.

Authors:  Min-Shan Tsai; Chien-Hua Huang; Chia-Ying Tsai; Huei-Wen Chen; Hsin-Chen Lee; Hsaio-Ju Cheng; Chiung-Yuan Hsu; Tzung-Dau Wang; Wei-Tien Chang; Wen-Jone Chen
Journal:  Intensive Care Med       Date:  2011-09-28       Impact factor: 17.440

2.  Atorvastatin increases oxidative stress and modulates angiogenesis in Ossabaw swine with the metabolic syndrome.

Authors:  Nassrene Y Elmadhun; Antonio D Lassaletta; Louis M Chu; Yuhong Liu; Jun Feng; Frank W Sellke
Journal:  J Thorac Cardiovasc Surg       Date:  2012-09-17       Impact factor: 5.209

Review 3.  Pharmacotherapy for end-stage coronary artery disease.

Authors:  Neel R Sodha; Louis M Chu; Munir Boodhwani; Frank W Sellke
Journal:  Expert Opin Pharmacother       Date:  2010-02       Impact factor: 3.889

4.  Effect of hypercholesterolemia on myocardial necrosis and apoptosis in the setting of ischemia-reperfusion.

Authors:  Robert M Osipov; Cesario Bianchi; Jun Feng; Richard T Clements; Yuhong Liu; Michael P Robich; Hilary P Glazer; Neel R Sodha; Frank W Sellke
Journal:  Circulation       Date:  2009-09-15       Impact factor: 29.690

Review 5.  Coronary microvascular adaptations distal to epicardial artery stenosis.

Authors:  Daphne Merkus; Judy Muller-Delp; Cristine L Heaps
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-05-07       Impact factor: 5.125

Review 6.  Modulation of Hypercholesterolemia-Induced Oxidative/Nitrative Stress in the Heart.

Authors:  Csaba Csonka; Márta Sárközy; Márton Pipicz; László Dux; Tamás Csont
Journal:  Oxid Med Cell Longev       Date:  2015-12-14       Impact factor: 6.543

7.  Atorvastatin impairs liver mitochondrial function in obese Göttingen Minipigs but heart and skeletal muscle are not affected.

Authors:  Liselotte Bruun Christiansen; Tine Lovsø Dohlmann; Trine Pagh Ludvigsen; Ewa Parfieniuk; Michal Ciborowski; Lukasz Szczerbinski; Adam Kretowski; Claus Desler; Luca Tiano; Patrick Orlando; Torben Martinussen; Lisbeth Høier Olsen; Steen Larsen
Journal:  Sci Rep       Date:  2021-01-26       Impact factor: 4.379

8.  HMG-CoA reductase inhibitors induce apoptosis of lymphoma cells by promoting ROS generation and regulating Akt, Erk and p38 signals via suppression of mevalonate pathway.

Authors:  X-F Qi; L Zheng; K-J Lee; D-H Kim; C-S Kim; D-Q Cai; Z Wu; J-W Qin; Y-H Yu; S-K Kim
Journal:  Cell Death Dis       Date:  2013-02-28       Impact factor: 8.469

9.  Quantitative evaluation of contrast-enhanced ultrasonography in the diagnosis of chronic ischemic renal disease in a dog model.

Authors:  Yi Dong; Wenping Wang; Jiaying Cao; Peili Fan; Xiyuan Lin
Journal:  PLoS One       Date:  2013-08-01       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.